Keros Therapeutics (KROS)

• Market cap: $417M
• 1 day: 2.39%
• 5 days: -6.29%
• 1 month: -7.39%
• 3 months: -36.15%
• 6 months: -82.84%
• Year to date: -35.43%
• 1 year: -83.93%
• 5 years: -48.80%
• 10 years: -48.80%
• Sector: Healthcare
• Industry: Biotechnology

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

159% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 29

3% less call options, than puts

Call options by funds: $10.8M | Put options by funds: $11.2M

5% less first-time investments, than exits

New positions opened: 38 | Existing positions closed: 40

1% less funds holding

Funds holding: 163 [Q3] → 161 (-2) [Q4]

2.47% less ownership

Funds ownership: 93.19% [Q3] → 90.72% (-2.47%) [Q4]

60% less funds holding in top 10

Funds holding in top 10: 5 [Q3] → 2 (-3) [Q4]

71% less capital invested

Capital invested by funds: $2.03B [Q3] → $582M (-$1.45B) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $15 46% upside
• Avg. target: $25 143% upside
• High target: $41 299% upside

7 analyst ratings

• positive: 5 71%
• neutral: 2 29%
• negative: 0 0%

Wedbush Yun Zhong 0% 1-year accuracy 0 / 1 met price target	46% upside $15	Neutral Reiterated	1 Apr 2025
HC Wainwright & Co. Andrew Fein 28% 1-year accuracy 102 / 358 met price target	289% upside $40	Buy Reiterated	1 Apr 2025
Wells Fargo Tiago Fauth 22% 1-year accuracy 2 / 9 met price target	153% upside $26	Overweight Maintained	27 Feb 2025
Piper Sandler Joseph Catanzaro 0 / 0 met price target	46% upside $15	Overweight Maintained	17 Jan 2025
Wedbush Andreas Argyrides 36% 1-year accuracy 4 / 11 met price target	46% upside $15	Neutral Downgraded	17 Jan 2025